Posted by Michael Wonder on 04 Feb 2023
European Commission approves label expansion of Roche’s Hemlibra to include people with moderate haemophilia A in the EU
1 February 2023 - The approval is based on the HAVEN 6 results, where Hemlibra demonstrated effective bleed control and a favourable safety profile in people with moderate haemophilia A without inhibitors.
Roche today announced that the European Commission approved the expansion of the Hemlibra (emicizumab) European Union marketing authorisation.
